NFL Biosciences SAS
Save
18.95M
Market cap
–
Current P/E
–
Forward P/E
About
Health care
Sector
Biotechnology
Industry
NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. Its natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.
Similar securities
Based on sector and market capitalization
Report issue